Onconova Therapeutics Inc... (ONTX)
Onconova Therapeutics Statistics
Share Statistics
Onconova Therapeutics has 21M shares outstanding. The number of shares has increased by 0% in one year.
| Shares Outstanding | 21M |
| Shares Change (YoY) | 0% |
| Shares Change (QoQ) | 0% |
| Owned by Institutions (%) | n/a |
| Shares Floating | n/a |
| Failed to Deliver (FTD) Shares | 701 |
| FTD / Avg. Volume | 0.55% |
Short Selling Information
| Short Interest | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | n/a |
Valuation Ratios
The PE ratio is -0.83 and the forward PE ratio is null. Onconova Therapeutics's PEG ratio is -0.36.
| PE Ratio | -0.83 |
| Forward PE | n/a |
| PS Ratio | 69.24 |
| Forward PS | n/a |
| PB Ratio | 1.47 |
| P/FCF Ratio | -0.87 |
| PEG Ratio | -0.36 |
Enterprise Valuation
Onconova Therapeutics has an Enterprise Value (EV) of -5.17M.
| EV / Sales | -22.88 |
| EV / EBITDA | 0.25 |
| EV / EBIT | 0.29 |
| EV / FCF | 0.29 |
Financial Position
The company has a current ratio of 2.46, with a Debt / Equity ratio of -316247.81.
| Current Ratio | 2.46 |
| Quick Ratio | 2.3 |
| Debt / Equity | -316247.81 |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | 0 |
Financial Efficiency
Return on Equity is -177.55% and Return on Invested Capital is 0%.
| Return on Equity | -177.55% |
| Return on Assets | -83.53% |
| Return on Invested Capital | 0% |
| Revenue Per Employee | $14,125 |
| Profits Per Employee | $-1,184,250 |
| Employee Count | 16 |
| Asset Turnover | 0.01 |
| Inventory Turnover | -159.15K |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | 0% |
Stock Price Statistics
The stock price has increased by 55.91% in the last 52 weeks. The beta is 1.35, so Onconova Therapeutics's price volatility has been higher than the market average.
| Beta | 1.35 |
| 52-Week Price Change | 55.91% |
| 50-Day Moving Average | 0.8 |
| 200-Day Moving Average | 0.77 |
| Relative Strength Index (RSI) | 36.95 |
| Average Volume (20 Days) | 126,338 |
Income Statement
In the last 12 months, Onconova Therapeutics had revenue of 226K and earned -18.95M in profits. Earnings per share was -0.9.
| Revenue | 226K |
| Gross Profit | 226B |
| Operating Income | -20.3M |
| Net Income | -18.95M |
| EBITDA | -20.28M |
| EBIT | n/a |
| Earnings Per Share (EPS) | -0.9 |
Balance Sheet
The company has 20.82M in cash and 0 in debt, giving a net cash position of 20.82M.
| Cash & Cash Equivalents | 20.82M |
| Total Debt | n/a |
| Net Cash | n/a |
| Retained Earnings | -482.63M |
| Total Assets | 18.17M |
| Working Capital | 8.73M |
Cash Flow
In the last 12 months, operating cash flow was -17.93M and capital expenditures -14K, giving a free cash flow of -17.95M.
| Operating Cash Flow | -17.93M |
| Capital Expenditures | -14K |
| Free Cash Flow | -17.95M |
| FCF Per Share | -0.86 |
Margins
Gross margin is 100000000%, with operating and profit margins of -8981.42% and -8384.07%.
| Gross Margin | 100000000% |
| Operating Margin | -8981.42% |
| Pretax Margin | -8384.07% |
| Profit Margin | -8384.07% |
| EBITDA Margin | -8974.34% |
| EBIT Margin | -8981.42% |
| FCF Margin | -7940.71% |
Dividends & Yields
ONTX does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Payout Ratio | n/a |
| Earnings Yield | -121.08% |
| FCF Yield | -114.68% |
Analyst Forecast
Currently there are no analyst rating for ONTX.
| Price Target | n/a |
| Price Target Difference | n/a |
| Analyst Consensus | n/a |
| Analyst Count | n/a |
Stock Splits
The last stock split was on May 21, 2021. It was a backward split with a ratio of 1:15.
| Last Split Date | May 21, 2021 |
| Split Type | backward |
| Split Ratio | 1:15 |
Scores
| Altman Z-Score | -39.46 |
| Piotroski F-Score | 3 |